Local BCNU and TMZ Delivery in Biodegradable Discs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for adult glioblastoma multiforme (GBM) face limitations due to poor central nervous system drug penetration and dose-limiting toxicities, necessitating the development of more effective chemotherapeutic strategies that minimize systemic toxicity and maximize local drug concentrations at the tumor site.
Innovation Solution
The combination of intracranial delivery of carmustine (BCNU) and temozolomide (TMZ) in biodegradable polymer discs, preferably with radiation therapy, achieves sustained release and enhanced efficacy by maximizing local drug concentrations while minimizing systemic exposure, thereby improving survival rates and reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher doses of temozolomide are administered to increase efficacy, then tumor treatment effectiveness improves, but dose-limiting myelosuppression and systemic toxicity increase
Solution Approach 1:
The patent applies local quality by delivering temozolomide directly to the tumor site through implantable devices or convection-enhanced delivery, creating high drug concentrations locally while maintaining low systemic levels. This resolves the contradiction by enabling effective dosing at the target site without proportionally increasing systemic toxicity.
Solution Approach 2:
The patent uses biodegradable polymer matrices and targeted delivery systems as intermediaries to transport temozolomide selectively to the tumor. These intermediaries control drug release kinetics and spatial distribution, allowing high local efficacy while limiting systemic exposure and associated toxicities.
2Reliability
If local delivery of chemotherapeutic agents is used to maximize drug concentrations at the tumor site, then efficacy improves, but the number of available agents and treatment options remains limited
Solution Approach 1:
The patent employs universal biodegradable polymer delivery systems that can accommodate multiple different chemotherapeutic agents including temozolomide, BCNU, and other alkylating agents. This multi-functional platform resolves the contradiction by providing a single versatile delivery mechanism that supports various drug options, thereby expanding treatment adaptability while maintaining effective local concentrations.
3Reliability
If systemic chemotherapy is administered to treat glioblastoma, then some therapeutic effect is achieved, but poor central nervous system drug penetration limits effectiveness
Solution Approach 1:
The patent extracts the delivery mechanism from systemic circulation and places it directly at the tumor site through implantable devices. This bypasses the blood-brain barrier limitation by delivering drugs directly into the CNS tissue, thereby achieving adequate drug penetration and therapeutic effect that cannot be obtained through systemic administration alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly prolongs survival in glioma models, with 75% long-term survivors in the 9L gliosarcoma model and improved survival in the F98 glioma model, demonstrating superior efficacy compared to single-agent or systemic treatments, and no systemic toxicity observed.
Implementation Method 1
local delivery of agents to the site of the tumor to achieve maximal drug concentrations
Implementation Method 2
biodegradable polymer containing the alkylating agent Carmustine (BCNU)
Data Source
AI summary
The additive effect of combined intracranial carmustine (“BCNU”) with intracranial temozolomide (“TMZ”), and particularly in combination with radiation (“XRT”), in the treatment of two rat intracranial glioma models, the 9L gliosarcoma and the F98 glioma, demonstrates that local delivery of both drugs, especially in combination with radiation, is far more effective than delivery of either drug alone or one systemically and one locally, either with or without radiation. The triple therapy showed a significant improvement in survival when compared to controls (p=0.0004), local BCNU (p=0.0043), oral TMZ (p=0.0026), local TMZ (p=0.0105), and the combinations of either BCNU and XRT (p=0.0378) or oral TMZ and local BCNU (p=0.0154).